Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Bictegravir/Emtricitabine/Tenofovir alafenamide

Thursday 15 February 2018

Interactions with bictegravir/emtricitabine/tenofovir alafenamide are now included on the website, HIV i Chart app and printable charts. For ease of viewing on small screens, the listing appears as “Bictegravir/FTC/TAF”.

Bictegravir/emtricitabine/tenofovir alafenamide (Bictarvy®) is a fixed dose combination and is indicated as a complete regimen for the treatment of HIV-1 infection. It was recently approved by the FDA and is under evaluation by the European Medicines Agency (EMA).

SPONSORS
Sponsor logo janssen Sponsor logo gilead Sponsor logo msd Sponsor logo viiv
EDITORIAL SPONSORS
Hiv  glasgow 2018 cmyk logo Eacs logo 2014 Bhiva 2018 Basel text
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016